Aromatase inhibitors (AIs), such as anastrozole, constitute an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent ER and PR-positive postmenopausal breast cancer patients [7,8]. The gene discussed is ESR1; the disease is breast cancer.